| 17199797 |
DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH: Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology. 2006 Dec;11(6):555-9.
AIM: To assess the impact of the administration of ergocalciferol on serum parathyroid hormone levels at different stages of chronic kidney disease (CKD). METHODS: A continuous series of 85 patients with stages 3-5 CKD but excluding patients on dialysis referred to the Kaiser Kidney Program were followed. Baseline serum intact parathyroid hormone (iPTH) and serum 25 (OH) D levels were measured. All patients were administered ergocalciferol in doses ranging from 800 iu/day to 100,000 iu/week. We obtained serum levels of iPTH and 25 (OH) D for a post-treatment endpoint after a median treatment period of 90 days. RESULTS: Pre- and post-treatment serum iPTH levels displayed a mean difference of 2.8 pmol/L (95% CI 1.3-4.4, P < 0.001). Patients with stage 4 CKD had a mean difference of 3.6 pmol/L (95% CI 1.7-5.5, P < 0.001) between pre- and post-iPTH levels. Serum iPTH levels decreased among CKD stages 3 and 5, but were not statistically significant. All CKD groups analysed in the present study had significant increases in serum 25 (OH) D levels. None of the study population required cessation of vitamin D therapy and no adverse outcomes were reported. CONCLUSION: Ergocalciferol supplementation appears a safe and effective treatment for CKD populations which may raise levels of serum 25 (OH) D levels and decrease iPTH levels. |
13(0,0,2,3) |